Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Executive Officer

EVP & Chief Technology Officer

EVP & Chief Financial Officer

EVP & Chief Medical Officer

Chief Medical Officer

Chief Administrative Officer

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious dise...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-03	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-04-01	Premium	sold	Premium	Premium	Premium	EVP & Chief Technology Officer
2024-03-27	Premium	sold	Premium	Premium	Premium	EVP & Chief Financial Officer
2024-02-26	Premium	sold	Premium	Premium	Premium	-
2024-02-22	Premium	acquired	Premium	Premium	Premium	EVP & Chief Technology Officer
2024-02-22	Premium	sold	Premium	Premium	Premium	EVP & Chief Medical Officer
2024-02-22	Premium	sold	Premium	Premium	Premium	-
2024-02-22	Premium	acquired	Premium	Premium	Premium	EVP & Chief Financial Officer
2024-02-22	Premium	sold	Premium	Premium	Premium	EVP & Chief Technology Officer
2024-02-22	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-02-20	Premium	sold	Premium	Premium	Premium	-
2024-02-16	Premium	sold	Premium	Premium	Premium	EVP & Chief Medical Officer
2024-02-16	Premium	sold	Premium	Premium	Premium	-
2024-01-02	Premium	acquired	Premium	Premium	Premium	EVP & Chief Medical Officer
2023-10-19	Premium	sold	Premium	Premium	Premium	-
2023-10-19	Premium	acquired	Premium	Premium	Premium	-
2023-10-17	Premium	sold	Premium	Premium	Premium	-
2023-10-17	Premium	acquired	Premium	Premium	Premium	-
2023-09-15	Premium	acquired	Premium	Premium	Premium	-
2023-09-15	Premium	sold	Premium	Premium	Premium	-
2023-06-30	Premium	sold	Premium	Premium	Premium	-
2023-06-30	Premium	sold	Premium	Premium	Premium	-
2023-06-29	Premium	sold	Premium	Premium	Premium	-

VIR - Vir Biotechnology Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for VIR